drugset / Trial / NCT07709000
A Clinical Trial of MK-1045 in People With B-cell Cancer (MK-1045-006)
Non-randomizedSequentialSingle-blindTreatment
Summary
Researchers are looking for new ways to treat people with B-cell cancers. In this trial, researchers will look at chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). These are blood cancers that affect B-cells in the blood, bone marrow, or lymph nodes. The goals of this trial are to learn about: * The safety of MK-1045 and if participants tolerate it. Tolerate means participants will receive trial treatment unless they need to stop treatment due to health problems. * The number of participants who respond. Respond means the number of cancer cells goes down or signs of cancer go away.
Timeline
- Start
- 2026-08-21
- Primary completion
- 2033-11-16
- Completion
- 2033-11-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MK-1045 | Other / unclassified | 40 mg | Intravenous |
| Subject | MK-1045 | Other / unclassified | 90 mg | Intravenous |
| Background | Acetaminophen | Small molecule | — | Oral |
| Background | Complarate® | Unknown | — | Intravenous |
| Background | Dexamethasone | Small molecule | — | Intravenous |
| Background | Diphenhydramine | Unknown | — | — |
| Background | Siltuximab | Monoclonal antibody | — | Intravenous |
| Background | Tocilizumab | Monoclonal antibody | — | Intravenous |